• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Alzheimer's Q&A

What is dementia?


Dementia is an umbrella term used to describe a set of symptoms that can include memory loss, confusion, and difficulties with language. There are many different types of dementia. These occur when the brain is affected by certain diseases or conditions.



What is Alzheimer's dementia?


Alzheimer’s disease can cause a specific type of dementia that usually develops slowly and gets worse over time. During the disease, proteins build up in the brain to form structures called ‘plaques’ and ‘tangles’. This can lead to the loss of connections between nerve cells, and eventually to the loss of brain tissue. There are currently no treatments or cures for Alzheimer’s dementia.



How many people are affected by Alzheimer’s dementia?


There are an estimated 46.8 million people worldwide living with dementia in 2015 and this figure is set to rise to 131.5 million by 2050. (World Alzheimer Report 2016). Alzheimer’s disease is the leading cause of dementia globally. It affects around seven million people in Europe.



Why are you focusing on prevention rather than treatment?


Attempts to develop new therapies for treating Alzheimer’s disease have so-far been unsuccessful. It is a progressive disorder and it is well known that the signs of the disease – plaques and tangles – can be found in the brain decades before the first symptoms appear. Researchers believe that early intervention may be a more effective way to tackle the condition.


Share this page
FacebookTwitterLinkedInGoogle+
Latest News
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
    2022-03-10
  • New paper on the affordances of clinical research participation
    2022-01-14
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Registration is now open for the upcoming #NeuroToolKit Data Hackathon! Join fellow experts and investigate biomarkers in #Alzheimers disease. You'll work with @IMI_EPAD datasets by utilizing @AlzData resources. For more information: ep-ad.org/addi-neurotool… twitter.com/IMI_EPAD/statu…

reply retweet favorite
6:56 am · 2022-05-18
Twitter
EPAD
EPAD
@IMI_EPAD

📢 Four abstracts with @IMI_EPAD data have been accepted for #AAIC22, including 3 posters & 1 oral presentation! Looking forward to meeting you in San Diego! @LuigiLorenzini1 @GregorySarah @fpmaragall @amsterdamumc @CenDemPrevent twitter.com/alzassociation…

reply retweet favorite
10:45 am · 2022-04-28
Twitter
EPAD
EPAD
@IMI_EPAD

The @IMI_EPAD Research Participant Panel has been established to give participants an active role in influencing the design, conduct and reporting of research. Want to know more? Watch this recording. #31AEC @AlzheimerEurope @IMI2_NEURONET @CenDemPrevent youtu.be/GObdDorTOE0?t=…

reply retweet favorite
6:42 am · 2022-04-20
Twitter
EPAD
EPAD
@IMI_EPAD

Listen to @GregorySarah from @CenDemPrevent talking about the associations between stressful life events, #Alzheimer's disease biomarkers and cognition in the @IMI_EPAD Longitudinal Cohort Study at the @AlzheimerEurope conference #31AEC. youtu.be/loZSphK4s9g

reply retweet favorite
9:45 am · 2022-04-11
Twitter
EPAD
EPAD
@IMI_EPAD

We are delighted to announce that the first study participant for the @IMI_EPAD Scotland study was seen today! It is the first national initiative to have started study recruitment. @craig_ritchie68 @CenDemPrevent For more info, visit our website⤵️ ep-ad.org/first-national… pic.twitter.com/4Z46mokA88

reply retweet favorite
12:44 pm · 2022-04-07
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT